COMP <GO>
XCUR vs ENVB // EV/EBITDA & P/E VALUATION
Exicure Inc. (NASDAQ) VS. Enveric Biosciences Inc. (NASDAQ) • 15-METRIC TALLY: XCUR 0
— ENVB 3
■ METRIC PARITY
LAST: $0.93 (-8.04%) • MKT CAP: $6.1M
valuation
—
LAST: $1.46 (-0.68%) • MKT CAP: $6.5M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (XCUR VS. ENVB)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | XCUR | ENVB | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 3/9 | -1.00 | ENVB | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 43.0 | 48.2 | -5.15 | ENVB | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $6.1M | $6.5M | -$415.6K | ENVB | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | XCUR REV | ENVB REV | XCUR GROSS % | ENVB GROSS % | XCUR FCF | ENVB FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$8.6M | -$8.1M |
| FY 2024 | $500.0K | $0 | — | — | -$2.9M | -$7.7M |
| FY 2023 | $0 | $0 | — | — | -$10.4M | -$14.1M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
XCUR // BETA —
ENVB // BETA —